MDL Track
MDL 3043
S.D.N.Y.
Acetaminophen ASD/ADHD products liability
58 pending
Pharmaceutical · claims focused on acetaminophen exposure and alleged developmental injuries
Defendant
Johnson & Johnson Consumer Inc.
MDL / Track
MDL 3043
S.D.N.Y.
Judge
Judge Denise L. Cote
Plaintiffs
roughly 82 pending (58 per JPML's March 2, 2026 report, plus ~24 new filings tracked since)
Bellwether / Trial
No verdicts yet
Settlement Status
Track litigations for free. Save this matter, capture notes, and monitor live signals.
Case overview
The Second Circuit revived MDL No. 3043 in July 2026, reversing Judge Denise L. Cote's August 2024 summary judgment that had dismissed roughly 500 federal cases after excluding plaintiffs' general causation experts under Daubert. In re Acetaminophen ASD/ADHD Products Liability Litigation, 1:22-md-03043 (S.D.N.Y.), now returns to the district court for further proceedings on expert admissibility. No settlement or trial date exists.
Causation Theory
Plaintiffs' theory rests on epidemiological studies finding a 20-30% increased risk of autism spectrum disorder and ADHD with prolonged prenatal acetaminophen exposure, including a 2018 American Journal of Epidemiology meta-analysis and a 2019 JAMA Psychiatry study showing dose-response relationships in umbilical cord blood. The 2021 Consensus Statement summarized 29 observational studies covering over 220,000 mother-child pairs and called for precautionary action, but explicitly did not conclude a causal relationship exists. The FDA has consistently rejected a causal interpretation, stating in 2022-2023 reviews and an October 2025 Notice to Physicians that no clear evidence establishes causality, though it opened a Tracked Safety Issue in 2014 and continues periodic review.
Case Management Orders
Litigation status
The Second Circuit revived MDL 3043 on July 13, 2026, vacating Judge Denise Cote's exclusion of three of five plaintiffs' general causation experts in Rutledge v. Walgreen Co. and remanding roughly 500 dismissed cases to the Southern District of New York. The panel (Calabresi, Lynch, Lee) held Judge Cote exceeded her discretion as a gatekeeper, but affirmed exclusion of two experts; defendants are seeking rehearing en banc and have signaled renewed Daubert challenges on remand.
MDL Track
MDL 3043
S.D.N.Y.
Acetaminophen ASD/ADHD products liability
58 pending
State Court Activity
Parallel state court cases continue in CA, PA, NY, DE and other jurisdictions applying independent evidentiary standards; no state verdicts yet
MDL 3043 Leadership
Plaintiff Leadership
Plaintiffs' Co-Lead Counsel
Plaintiffs' Liaison Counsel
Plaintiffs' Executive Committee
Law & Briefing Committee Chair
Early Vetting/Bellwether Selection Committee Chair
Discovery/ESI Committee Chair
Science & Expert Committee Chair
Settlement/Lien Resolution Committee Chair
Plaintiffs' Steering Committee
Defense Leadership
Defense Liaison Counsel
Retailer Liaison Committee
Manufacturer Liaison
Geographic exposure
MDL 3043 encompasses 1,500+ federal cases alleging prenatal acetaminophen exposure causes autism/ADHD; defendants include Johnson & Johnson/Kenvue, Walmart, CVS, Walgreens, Costco, Rite Aid. No global settlement. State SOL tolling rules for minors create variable filing windows nationwide.
MDL 3043 (In re: Acetaminophen ASD/ADHD Products Liability Litigation) revived July 2026 after Second Circuit reversal of Judge Denise Cote's Daubert exclusion; 500+ cases reinstated, litigation returns to district court for causation proceedings — 637 F.Supp.3d 1372 (J.P.M.L. 2022)
Bellwether death case Terry v. McNeil-PPC (Civil Action No. 2:12-cv-07263, MDL 2436) — decedent Denice Hayes purchased, used, and died in Alabama; court applied Alabama wrongful death law permitting uncapped punitive damages, rejecting New Jersey's $350,000 cap — 181 F.Supp.3d 278 (E.D. Pa. 2016)
State DEP suit against Pfizer, Johnson & Johnson, Honeywell over TCE groundwater contamination at former Warner-Lambert pharmaceutical plant, Morris Plains; aquifer supplies 900M+ gallons/day serving majority of state population — complaint filed October 2025 per Inside Climate News/PhillyVoice
16-resident state court suit against Amphenol/Honeywell over chlorinated solvent contamination at 980 Hurricane Road and 400 N. Forsythe St. sites; EPA cleanup ongoing with vapor mitigation systems installed in affected homes — Marion Superior Court 3, filed December 6, 2024 per The Republic News
Key defendants
Johnson & Johnson Consumer Inc.
Role: Manufacturer
Core manufacturer defendant in MDL 3043 (S.D.N.Y., Judge Cote). Survived motion to dismiss in Chapman v. Walmart, 22cv8830; court found Nevada failure-to-warn claims adequately pled. Preemption defense rejected in Nov. 2022 order. Currently facing general causation discovery and Daubert briefing.
Johnson & Johnson
Role: Parent/Former Manufacturer
Named in Texas AG suit (Panola County, filed Oct. 2025) for fraudulent transfer of Tylenol liabilities to Kenvue. Alleged to have known of ASD/ADHD risks. State seeks injunctive relief and penalties under Texas DTPA and UFTA.
Kenvue, Inc.
Role: Successor Manufacturer
Delaware successor entity that allegedly received fraudulent transfer of Tylenol liabilities from J&J. Named as defendant in Texas AG action. Principal place of business New Jersey; conducts business in Texas.
Kenvue Brands LLC
Role: Successor Manufacturer
f/k/a Johnson & Johnson Consumer Inc. Named alongside Kenvue, Inc. in Texas AG fraudulent transfer suit. Same litigation posture as Kenvue, Inc.—primary exposure is successor liability and UFTA claims.
Walmart, Inc.
Role: Retailer Defendant
Named retailer defendant in MDL 3043. Survived motion to dismiss in Chapman, 22cv8830. Court rejected argument that retailer lacked duty to warn. Currently in general causation discovery phase alongside other retailers.
| Defendant | Role | Intelligence Note |
|---|---|---|
| Johnson & Johnson Consumer Inc. | Manufacturer | Core manufacturer defendant in MDL 3043 (S.D.N.Y., Judge Cote). Survived motion to dismiss in Chapman v. Walmart, 22cv8830; court found Nevada failure-to-warn claims adequately pled. Preemption defense rejected in Nov. 2022 order. Currently facing general causation discovery and Daubert briefing. |
| Johnson & Johnson | Parent/Former Manufacturer | Named in Texas AG suit (Panola County, filed Oct. 2025) for fraudulent transfer of Tylenol liabilities to Kenvue. Alleged to have known of ASD/ADHD risks. State seeks injunctive relief and penalties under Texas DTPA and UFTA. |
| Kenvue, Inc. | Successor Manufacturer | Delaware successor entity that allegedly received fraudulent transfer of Tylenol liabilities from J&J. Named as defendant in Texas AG action. Principal place of business New Jersey; conducts business in Texas. |
| Kenvue Brands LLC | Successor Manufacturer | f/k/a Johnson & Johnson Consumer Inc. Named alongside Kenvue, Inc. in Texas AG fraudulent transfer suit. Same litigation posture as Kenvue, Inc.—primary exposure is successor liability and UFTA claims. |
| Walmart, Inc. | Retailer Defendant | Named retailer defendant in MDL 3043. Survived motion to dismiss in Chapman, 22cv8830. Court rejected argument that retailer lacked duty to warn. Currently in general causation discovery phase alongside other retailers. |
Timeline
MDL 3043 Formed in SDNY
Judicial Panel on Multidistrict Litigation consolidated federal acetaminophen ASD/ADHD cases as MDL No. 3043, In re Acetaminophen – ASD-ADHD Products Liability Litigation, before Senior District Judge Denise Cote in the Southern District of New York. Approximately 500-700 cases transferred.
Cote Denies Preemption Dismissal
Judge Cote denied Walmart's motion to dismiss on federal preemption grounds, ruling FDA regulations did not bar retailers from adding warnings to generic acetaminophen labels. Similar denials followed in April 2023.
Cote Excludes All Five General Causation Experts
Judge Cote issued Daubert ruling excluding all plaintiffs' general causation experts — Drs. Andrea Baccarelli, Eric Hollander, Brandon Pearson, Robert Cabrera, and Stan Louie — finding methodologies unreliable under Federal Rule of Evidence 702.
Cote Excludes Replacement Expert Ness
Judge Cote excluded replacement expert Dr. Roberta Ness in 84-page opinion, finding her analysis 'result driven' and lacking 'objective or rigorous application of scientific methodology.' Ness had been plaintiffs' final general causation witness.
Summary Judgment Dismisses Entire MDL
Judge Cote granted summary judgment to all defendants and ordered clerk to close all pending MDL cases. Ruling applied to approximately 550 served plaintiffs. Plaintiffs' attempt to rely on defense expert Dr. Stephen Faraone's isolated statements rejected.
Plaintiffs Appeal to Second Circuit
Plaintiffs filed appeal to U.S. Court of Appeals for the Second Circuit, challenging Daubert exclusions and summary judgment. Appeals consolidated under Case No. 24-2360.
Second Circuit Holds Oral Argument
Second Circuit panel heard oral argument on November 17, 2025. Two of three judges questioned whether Judge Cote had been overly aggressive in excluding expert testimony. Argument originally scheduled for October 2025.
FDA Initiates Labeling Update
FDA initiated labeling update for acetaminophen products acknowledging potential link between prenatal exposure and increased autism/ADHD risk. First federal regulatory acknowledgment of plaintiffs' core scientific theory. Plaintiffs cited action in letter to Second Circuit.
Second Circuit Revives MDL, Reinstates Three Experts
Unanimous Second Circuit panel reversed Judge Cote's exclusion of three of five experts — Baccarelli, Hollander, and Pearson — finding district court exceeded discretion. Upheld exclusion of Cabrera and Louie. 64-page opinion noted new studies published since 2023 ruling. More than 500 cases remanded to SDNY for further proceedings. No causation finding made.
Statute of limitations
Federal preemption defenses rejected in MDL 22-3043 per Judge Cote's rulings, but general causation Daubert standard presents threshold barrier. Minor tolling varies by state; intake must verify date of majority and discovery timing. No active revival statutes identified as of March 2026.
New York
3 years from discovery
Rule: CPLR § 214(2) products liability; discovery rule applies for latent injuries
Discovery: Accrues when injury is discovered or should have been discovered through reasonable diligence; for minors, tolling until age 18 plus 3 years
MDL 22-3043 (Cote, J.) reopened Nov. 12, 2024 after closure Aug. 26, 2024; new filings accepted. Daubert hearing completed Dec. 2023; general causation experts largely excluded per Dec. 18, 2023 order (Dkt. 1381). Intake viable but causation hurdles remain.
California
2 years from discovery
Rule: Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988)
Discovery: Accrues when plaintiff knows or should know of injury and its probable cause; minor tolling until age 18
No revival statute active. Significant plaintiff pool given birth cohort exposure data.
Texas
2 years from discovery
Rule: Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies
Discovery: Accrues when injury becomes inherently undiscoverable and objectively apparent to reasonable person
Judge Cote dismissed Texas-law complaints without prejudice due to Texas statutory 'safe harbor' preemption for retailers (Tex. Civ. Prac. & Rem. Code § 82.007). J&J claims remain viable but retailer claims face preemption barrier.
⚠Florida
2 years from discovery
Rule: Fla. Stat. § 95.11(3)(a), (e); reduced from 4 years effective March 24, 2023 (HB 837)
Discovery: Accrues when facts giving rise to cause of action are discovered or should have been discovered
Legislative reduction from 4 to 2 years applies prospectively; transitional claims may exist. No minor tolling beyond age 18.
Pennsylvania
2 years from discovery
Rule: 42 Pa. Cons. Stat. § 5524(2); discovery rule applies
Discovery: Accrues when plaintiff knows or reasonably should know of injury and its cause; minor tolling until age 18
No revival statute. Large birth cohort in Philadelphia metro area.
Ohio
2 years from discovery
Rule: Ohio Rev. Code § 2305.10(C); discovery rule applies
Discovery: Accrues when injury is discovered or should have been discovered with reasonable diligence; minor tolling until age 18 plus 2 years
No revival statute pending.
Illinois
2 years from discovery
Rule: 735 ILCS 5/13-202; discovery rule applies per Knox College v. Celotex Corp., 574 N.E.2d 677 (Ill. 1991)
Discovery: Accrues when injury and its wrongful cause are discovered or should have been discovered; minor tolling until age 18 plus 2 years
No revival statute. Centralized birth records support exposure documentation.
| State | SOL | Rule | Discovery Rule | Notes |
|---|---|---|---|---|
| New York | 3 years from discovery | CPLR § 214(2) products liability; discovery rule applies for latent injuries | Accrues when injury is discovered or should have been discovered through reasonable diligence; for minors, tolling until age 18 plus 3 years | MDL 22-3043 (Cote, J.) reopened Nov. 12, 2024 after closure Aug. 26, 2024; new filings accepted. Daubert hearing completed Dec. 2023; general causation experts largely excluded per Dec. 18, 2023 order (Dkt. 1381). Intake viable but causation hurdles remain. |
| California | 2 years from discovery | Cal. Code Civ. Proc. § 335.1; discovery rule applies per Jolly v. Eli Lilly & Co., 751 P.2d 923 (Cal. 1988) | Accrues when plaintiff knows or should know of injury and its probable cause; minor tolling until age 18 | No revival statute active. Significant plaintiff pool given birth cohort exposure data. |
| Texas | 2 years from discovery | Tex. Civ. Prac. & Rem. Code § 16.003; discovery rule applies | Accrues when injury becomes inherently undiscoverable and objectively apparent to reasonable person | Judge Cote dismissed Texas-law complaints without prejudice due to Texas statutory 'safe harbor' preemption for retailers (Tex. Civ. Prac. & Rem. Code § 82.007). J&J claims remain viable but retailer claims face preemption barrier. |
| ⚠Florida | 2 years from discovery | Fla. Stat. § 95.11(3)(a), (e); reduced from 4 years effective March 24, 2023 (HB 837) | Accrues when facts giving rise to cause of action are discovered or should have been discovered | Legislative reduction from 4 to 2 years applies prospectively; transitional claims may exist. No minor tolling beyond age 18. |
| Pennsylvania | 2 years from discovery | 42 Pa. Cons. Stat. § 5524(2); discovery rule applies | Accrues when plaintiff knows or reasonably should know of injury and its cause; minor tolling until age 18 | No revival statute. Large birth cohort in Philadelphia metro area. |
| Ohio | 2 years from discovery | Ohio Rev. Code § 2305.10(C); discovery rule applies | Accrues when injury is discovered or should have been discovered with reasonable diligence; minor tolling until age 18 plus 2 years | No revival statute pending. |
| Illinois | 2 years from discovery | 735 ILCS 5/13-202; discovery rule applies per Knox College v. Celotex Corp., 574 N.E.2d 677 (Ill. 1991) | Accrues when injury and its wrongful cause are discovered or should have been discovered; minor tolling until age 18 plus 2 years | No revival statute. Centralized birth records support exposure documentation. |
Live intelligence
AI litigation brief
Tylenol / APAP remains active mdl with 124 current signals in the accepted feed.
Overview
The Second Circuit revived MDL 3043 on July 13, 2026, vacating Judge Denise Cote's exclusion of three of five plaintiffs' general causation experts in Rutledge v. Walgreen Co. and remanding roughly 500 dismissed cases to the Southern District of New York. The panel (Calabresi, Lynch, Lee) held Judge Cote exceeded her discretion as a gatekeeper, but affirmed exclusion of two experts; defendants are seeking rehearing en banc and have signaled renewed Daubert challenges on remand.
Key developments
Trajectory
Court filings and press coverage are both active in MDL 3043, pointing to sustained litigation pressure rather than a one-off headline cycle. 6 live sources are contributing current context.
Editorial intelligence
MDL 3043 should stay on the lead docket watch because it is the primary consolidation vehicle for Tylenol.
Generated Sep 30, 2026, 10:00 AM UTC
124 events detected
Google News (73)
Tylenol Maker Fights Ruling That Revived 500 Autism Lawsuits - lawcommentary.com
Tylenol maker, pharmacy chains urge US appeals court to revisit decision over alleged autism link - Reuters
Tylenol Autism Lawsuit Annette Bening (CS5wuERqTB) - Mshale
Tylenol Autism ADHD Lawsuit January 13, 2023 Update: Keith Law Group Dominique Malonga (Rgco7ngDfv) - Mshale
Tylenol Autism ADHD Lawsuit April, 2023 Update Keith Law Group Borsa (AFisRu8VVa) - Mshale
Autism Lawsuit Tylenol/ADHD Tylenol Lawsuit Info Ty Gibbs (5Ul6NqE9i7) - Mshale
Tylenol Autism ADHD Lawsuit April 30, 2023 Update Final Keith Law Group Iga świątek (mnJbvN0aI7) - Mshale
Tylenol Autism & ADHD Lawsuit September, 11 2023 Update Keith Law Group Jet Fuel (uDFMpGLMpP) - Mshale
Tylenol Autism & ADHD Lawsuit August 2023 Update - Keith Law Group Doncaster Sheffield Airport (Pmk93P7Fqp) - Mshale
Tylenol Autism & ADHD Lawsuit October 3, 2023 Update Keith Law Group Apple Iphone 18 Pro Max (OxzbsgmqJ3) - Mshale
Tylenol & Acetaminophen Autism Litigation Nick Kurtz (0Cx7fihYRx) - Mshale
Acetaminophen Linked To ADHD & Autism From Use During Pregnancy | Tylenol Autism ADHD Lawsuit Centre Bell (nsQMblJTIX) - Mshale
What The Experts Are Saying About The Tylenol Autism Lawsuit Cardinals Vs Padres (lpp0ScvzAG) - Mshale
Tylenol Autism & ADHD Lawsuit Attorney Vande Mataram (ev2OiYBozu) - Mshale
Tylenol Autism Lawsuit - Acetaminophen Use During Pregnancy Volkswagen Polo (q5oXQxRrjz) - Mshale
Tylenol Autism & ADHD Lawsuit - Keith Law Group, Acetaminophen Attorneys Bears Schedule 2026 (BAjc5uyyjw) - Mshale
Tylenol Autism Lawsuit Gnonto (PpGhB6m9tH) - Mshale
A Victory For Plaintiffs In The Tylenol-Acetaminophen Autism Lawsuit Texas (cZEqjKIXZQ) - Mshale
Tylenol Autism & ADHD Lawsuit - Keith Law Group, Acetaminophen Attorneys Bears Schedule 2026 (Ajc5uyyjwQ) - Mshale
Tylenol Autism ADHD Lawsuit FAQ: How Do I Prove That I Took Tylenol? Keith Law Group Answers Soccer Zero Codes (dfR1DzaAMl) - Mshale
Tylenol Lawsuit Could Be Revived After White House's Baseless Claims Of Autism Link Blair Underwood (9c17Xe8VUr) - Mshale
Texas Sues Johnson & Johnson Over Tylenol-autism Link Claims Today Wordle Hints (voidGb6WBI) - Mshale
Texas Lawsuit Against Companies Behind Tylenol Asserts Unproven Claims Of Autism Risk Danny Devito (7OjtOqj84Q) - Mshale
Texas Lawsuit Against Companies Behind Tylenol Asserts Unproven Claims Of Autism Risk Dell Stock (bizRyqoHLa) - Mshale
How To File A Claim | Tylenol Autism Lawsuit Patrick Roy (fVSyzfVkeT) - Mshale
Tylenol Autism ADHD Lawsuit | Acetaminophen Use During Pregnancy Linked To Health Risk To Child Cheltenham Local Elections 2026 (NKqD5C7MJl) - Mshale
Tylenol Lawsuit Update June 2023 - Keith Law Group Marvel Rivals (m5CJp9uckr) - Mshale
Tylenol precedent threatens to tighten science vetting in Camp Lejeune toxic water trials - publicradioeast.org
Tylenol Autism ADHD Lawsuit April 30, 2023 Update Final Keith Law Group Carter Hart (u3Hhg9oeZO) - Mshale
Tylenol Autism & ADHD Lawsuit September, 11 2023 Update Keith Law Group Weather Hamilton (24qqnJgNgP) - Mshale
Ashley Keller Appeals Sanctions in Acetaminophen Cases, Asks to Reassign MDL to Another Judge - Law.com
Should You Stop Taking Tylenol During Pregnancy After the Lawsuit News? Here's What Doctors Want You to Know - Medical Daily
Appellate Court Revives Acetaminophen-Autism Cases Without Deciding the Merits of Plaintiffs’ Causation Theory - JD Supra
Opinion | Tylenol lawsuits are asking the wrong question about use in pregnancy - The Washington Post
Carlson Law Firm Accepting Clients After Appeals Court Allows Tylenol Lawsuits to Proceed - PR Newswire
Appeals Court Revives 500-Plus Tylenol Autism Lawsuits: What Pregnant Women Should Know About the Evidence - Medical Daily
How To File A Claim | Tylenol Autism Lawsuit Patrick Roy (VSyzfVkeT9) - Mshale
US court revives 550 lawsuits claiming Tylenol causes autism and ADHD. What does this ruling mean for science and the law? - Genetic Literacy Project
Pres. Trump ties autism to over-the-counter drug - FOX 13 Tampa Bay
Court revives lawsuits linking Tylenol use in pregnancy to autism, ADHD - The San Joaquin Valley Sun
2nd Circuit revives hundreds of suits linking Tylenol to autism - Michigan Lawyers Weekly
Appeals court revives Tylenol autism and ADHD lawsuits - MSN
US appeals court reverses dismissal of Tylenol cases - Jurist.org
Appeals court revives lawsuit against Tylenol brought by parents of children with autism - Denver Gazette
Tylenol-Autism Lawsuits Get New Life In Federal Court - cheddar.com
Appeals court revives Tylenol autism lawsuits against Kenvue - MSN
GLP-1s and Blinding Condition; Cyclosporiasis Source Found? Tylenol-Autism Lawsuits - MedPage Today
Private Lawsuits Linking Tylenol To Autism Revived - Talk 650 KSTE
Kenvue’s Tylenol lawsuits return, raising new brand reputation risks - eMarketer
Appeals Court Reverses Dismissal of Experts Linking Prenatal Acetaminophen to Autism, ADHD - Law.com
Health Brief: Tylenol lawsuits roar back - The Washington Post
Appeals court restores over 500 lawsuits alleging Tylenol linked to autism - Межа. Новини України.
US Appeals Court Revives Over 500 Tylenol Lawsuits Over Autism Claims - Health and Me
US appeals court revives hundreds of private lawsuits linking Tylenol to autism - ETPharma.com
US Appeals Court Revives Over 500 Lawsuits Linking "Tylenol" to Autism - صوت الإمارات
Judges allow lawsuit that ties Tylenol to autism to continue after it was dismissed for lack of ‘scientific evidence’ - AOL.com
Appeals court revives lawsuits claiming link between acetaminophen, ADHD and autism - The Hill
US appeals court revives hundreds of lawsuits linking Tylenol to autism - The Independent
Court Revives Lawsuits Tying Tylenol Use in Pregnancy to Autism and ADHD - GV Wire
Appeals Court Revives Private Lawsuits Linking Tylenol to Autism - Insurance Journal
Appeals Court Revives Lawsuits Tying Tylenol Use in Pregnancy to Autism and A.D.H.D. - The New York Times
Appeals court revives Tylenol autism, ADHD lawsuits - MSN
Tylenol Lawsuit Gets New Life, Shaking Kenvue Shares - Finimize
Kenvue's Tylenol Liability Nightmare: Appeals Court Reversal Ignites Fresh Legal Battle - Kavout | AI
Appeals Court Revives Lawsuits Alleging Tylenol Causes Autism and ADHD - WSJ
US appeals court revives private lawsuits linking Tylenol to autism - MSN
US appeals court revives private cases alleging Tylenol link to autism - France 24
KVUE Stock Dips After Court Revives Tylenol Autism Lawsuits - Stocktwits
Tylenol-Maker Kenvue Must Face Autism Lawsuits, Court Says (2) - Bloomberg Law News
US appeals court revives private lawsuits linking Tylenol to autism, ADHD - Classic Rock 103.5 WIMZ
US court revives 550 Tylenol lawsuits over autism claims - MSN
US Appeals court revives lawsuits linking Tylenol-maker Kenvue to autism (update) (KVUE:NYSE) - Seeking Alpha
Tylenol-Maker Kenvue Must Face Autism Claims, Appeals Court Says - Bloomberg.com
Pakistan journal of pharmaceutical sciences • Ma T • PMID 42708778 • Journal Article.
Health affairs scholar • Kadelka C • PMID 42787636 • Journal Article.
Developmental medicine and child neurology • Diz-Dios P • PMID 42773841 • Journal Article.
The Medical letter on drugs and therapeutics • Unknown author • PMID 42709899 • Journal Article.
Current pain and headache reports • Varrassi G • PMID 42730892 • Journal Article.
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket filed in JPML: The plaintiffs, represented by a mother on behalf of her minor children, are suing a major manufacturer and various retailers for distributing defective over-the-counter medications, specifically acetaminophen-based products like Tylenol. The lawsuit claims that using these medications during pregna
Addendum to Protective Order — Privileged Information for Phase 1 Discovery
This addendum incorporates into the existing protective order rules for withholding privileged information, requiring privilege logs that comply with Fed. R. Civ. P. 26(b)(5) and Local Civil Rule 26.2.
Addendum to Protective Order — Privileged Information for Phase 1 Discovery
This addendum incorporates into the existing protective order rules for withholding privileged information, requiring privilege logs that comply with Fed. R. Civ. P. 26(b)(5) and Local Civil Rule 26.2.
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc., WALMART INC.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33496964)Document filed by Vincent White..(Evola, Robert) (Entered: 09/25/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33490178)Document filed by Crystal Champeau(As guardian of minor plaintiff child R.C.), R. C., Crystal Champeau(Individually)..(Buchanan, David) (Entered: 09/24/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33484916)Document filed by Siam Ash..(Buchanan, David) (Entered: 09/23/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33475593)Document filed by John McArdle..(Buchanan, David) (Entered: 09/22/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson, Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33455300)Document filed by Jordan Ramos..(Evola, Robert) (Entered: 09/17/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33424653)Document filed by Amber Oldridge, Aya Jeffery..(Cuneo, Tessa) (Entered: 09/11/2026)
Acetaminophen - ASD/ADHD Products Liability Litigation
PACER docket entry from NYSD: COMPLAINT against Johnson & Johnson Consumer Inc.. (Filing Fee $ 405.00, Receipt Number ANYSDC-33420363)Document filed by Marie-Elaine Walker, Miles Xavier Walker..(Buchanan, David) (Entered: 09/11/2026)
Workbench
Sign in to save litigations, capture notes, and monitor live signals. Sign in for unlimited.
LexGenius Ranking
92Score
Court, news, and regulatory activity are elevated
Monitoring
Live
monitoring
Last: Sep 30, 2026, 10:00 AM UTC
Next: —
Source Monitoring
PACER
PACER
Google News
FAERS
PubMed
Event feed
124
events detected
AI Brief
Tylenol / APAP remains active mdl with 124 current signals in the accepted feed.
Overview
The Second Circuit revived MDL 3043 on July 13, 2026, vacating Judge Denise Cote's exclusion of three of five plaintiffs' general causation experts in Rutledge v. Walgreen Co. and remanding roughly 500 dismissed cases to the Southern District of New York. The panel (Calabresi, Lynch, Lee) held Judge Cote exceeded her discretion as a gatekeeper, but affirmed exclusion of two experts; defendants are seeking rehearing en banc and have signaled renewed Daubert challenges on remand.
Key developments
PACER court filing on Dec 31: Acetaminophen - ASD/ADHD Products Liability Litigation. ‖ lawcommentary.com news on Sep 14: Tylenol Maker Fights Ruling That Revived 500 Autism Lawsuits - lawcommentary.com. ‖ FAERS FDA alert on Jun 30: FAERS Filing 26940163: Autism spectrum disorder. ‖ PubMed research on Dec 1: PBPK modeling of intravenous/oral acetaminophen in healthy and pregnant individuals..
Generated Sep 30, 2026, 10:00 AM UTC
Tracked MDLs
MDL 3043
S.D.N.Y.
Acetaminophen ASD/ADHD products liability